Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.

Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):153-6.

PMID:
12794547
2.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
3.

Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L.

AIDS. 2006 Jan 9;20(2):217-22.

PMID:
16511414
4.

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.

Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL.

Pediatr Infect Dis J. 2001 Aug;20(8):803-5.

PMID:
11734746
5.

Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.

Chi BH, Wang L, Read JS, Sheriff M, Fiscus S, Brown ER, Taha TE, Valentine M, Goldenberg R.

AIDS. 2005 Nov 4;19(16):1857-64.

PMID:
16227794
6.

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.

Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT; HIVNET 023 Study Team.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):482-90.

PMID:
14657758
7.

A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.

Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, Boyle E, Chitsike I, Chipato T, Gottesman M, Silverman M.

Clin Infect Dis. 2007 Jan 1;44(1):111-9. Epub 2006 Nov 22.

PMID:
17143826
8.

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.

Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL.

J Infect Dis. 1998 Aug;178(2):368-74.

PMID:
9697716
9.

Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Bhadrakom C, Simonds RJ, Mei JV, Asavapiriyanont S, Sangtaweesin V, Vanprapar N, Moore KH, Young NL, Hannon WH, Mastro TD, Shaffer N.

AIDS. 2000 Mar 31;14(5):509-16.

PMID:
10780713
10.

Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, Mirochnick M.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):283-8.

PMID:
15735445
11.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Suksomboon N, Poolsup N, Ket-Aim S.

J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review.

PMID:
17489882
12.

Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.

Mugabo P, Els I, Smith J, Rabie H, Smith P, Mirochnick M, Steyn W, Hall D, Madsen R, Cotton MF.

S Afr Med J. 2011 Sep 5;101(9):655-8.

PMID:
21920159
13.

Nevirapine concentrations in newborns receiving an extended prophylactic regimen.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.

PMID:
18398973
14.

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.

Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, Stevens L, Peter T, Essex M, Connor JD, Mirochnick M.

J Infect Dis. 2005 Sep 1;192(5):720-7. Epub 2005 Jul 27.

PMID:
16088821
15.

Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.

Kunz A, Mugenyi K, Karcher H, Mayer A, Simo S, Ali M, Kurowski M, Harms G.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):562-5.

PMID:
17195764
16.

Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.

Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, Sinkala M, Smith PJ, Stringer EM, Stringer JS.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):220-3. doi: 10.1097/QAI.0b013e3181743969.

PMID:
18520682
17.

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.

AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5.

PMID:
19307941
18.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.

J Infect Dis. 2009 Nov 15;200(10):1490-7. doi: 10.1086/644598.

PMID:
19832114
19.

Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.

Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, Dhlamini P, Cohen S, Puren A, Steyn J, Heneine W, McIntyre JA.

AIDS. 2009 Apr 27;23(7):809-16. doi: 10.1097/QAD.0b013e328323ad49.

PMID:
19287298
20.

Concentrations of protease inhibitors in cord blood after in utero exposure.

Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL.

Pediatr Infect Dis J. 2002 Sep;21(9):835-8.

PMID:
12352805

Supplemental Content

Support Center